Pomerantz LLP is investigating claims on behalf of investors of Tyme Technologies, Inc. ("Tyme or the "Company").
Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
The investigation concerns whether Tyme and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On January 18, 2019, Tyme reported results from an open-label Phase 2 clinical trial evaluating the Company's product candidate SM-88 in patients with end-stage pancreatic cancer. Although Tyme characterized the results as positive, stating that SM-88 "improves survival," the trial did not include a control group, and Tyme's announcement merely compared survival data to historical controls. On this news, Tyme's stock price fell $1.32 per share, or 35.39%, to close at $2.41 per share on January 18, 2019.